Inspire Investing LLC Has $390,000 Stock Position in Health Catalyst, Inc. $HCAT

Inspire Investing LLC lifted its stake in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 36.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 103,494 shares of the company’s stock after purchasing an additional 27,582 shares during the quarter. Inspire Investing LLC owned 0.15% of Health Catalyst worth $390,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. SG Americas Securities LLC grew its holdings in shares of Health Catalyst by 195.2% during the 1st quarter. SG Americas Securities LLC now owns 80,825 shares of the company’s stock worth $366,000 after purchasing an additional 53,443 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Health Catalyst by 22.2% during the 1st quarter. Invesco Ltd. now owns 97,599 shares of the company’s stock worth $442,000 after purchasing an additional 17,725 shares in the last quarter. Petrus Trust Company LTA acquired a new stake in shares of Health Catalyst during the 1st quarter worth $432,000. Whetstone Capital Advisors LLC acquired a new stake in shares of Health Catalyst during the 1st quarter worth $7,724,000. Finally, Signal Advisors Wealth LLC acquired a new stake in shares of Health Catalyst during the 2nd quarter worth $645,000. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Price Performance

Health Catalyst stock opened at $2.90 on Wednesday. The company has a current ratio of 1.83, a quick ratio of 1.83 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $204.07 million, a PE ratio of -1.92 and a beta of 1.62. Health Catalyst, Inc. has a 12 month low of $2.52 and a 12 month high of $9.24. The stock has a 50-day moving average price of $3.08 and a two-hundred day moving average price of $3.63.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on HCAT. Wells Fargo & Company reduced their target price on Health Catalyst from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Monday, August 11th. Evercore ISI lowered their target price on Health Catalyst from $4.00 to $3.00 and set an “in-line” rating for the company in a research note on Wednesday, October 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Health Catalyst in a research note on Wednesday, October 8th. Stifel Nicolaus reduced their price target on shares of Health Catalyst from $5.50 to $4.50 and set a “hold” rating on the stock in a research note on Friday, August 8th. Finally, Citigroup downgraded shares of Health Catalyst from a “buy” rating to a “neutral” rating and reduced their price target for the company from $6.50 to $3.50 in a research note on Friday, August 8th. Three equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $4.55.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.